An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacodynamics of a Single Oral Dose of MT-1303 in Subjects With Inflammatory Bowel Disease.
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2014
At a glance
- Drugs Amiselimod (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 07 Jun 2017 Biomarkers information updated
- 04 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.